Synapse - Sara Kleban

Search Within

Sara F Kleban

Results (1)

Export to EndNote / Excel | PubMed

Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks

Journal Article

Sharma, S.; Kemeny, N.; Schwartz, G. K.; Kelsen, D.; O'reilly, E.; Ilson, D.; Coyle, J.; De Jager, R. L.; Ducharme, M. P.; Kleban, S.; more...
Clinical Cancer Research (2001)

Fulltext@MSK | Save